Search results
Found 122 matches for
An internationally recognised centre of excellence for biomedical and clinical research and teaching
Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders
General Innovation
16 February 2021
The University of Oxford announced today that it has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
BioEscalator’s Enara Bio partners with Boehringer Ingelheim to develop novel cancer immunotherapies
General Innovation
4 February 2021
Enara Bio, a start-up located in the University’s BioEsclator, has announced a strategic collaboration and licensing agreement with Boehringer Ingelheim, worth over €876M (£787M), to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.
Investigating New Treatment for Schizophrenia
General Innovation Research
21 January 2021
A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.
£100 million donation from Ineos to create new institute to fight antimicrobial resistance
Awards and Appointments General Innovation
19 January 2021
A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.
University spinout PepGen awarded major financing to target Duchenne muscular dystrophy
Awards and Appointments General Innovation
9 December 2020
PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.
£3M invested to drive forward early translation through five new Oxford-Bristol Myers Squibb Fellowships
Awards and Appointments General Innovation
9 December 2020
Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of £3M have been announced today*. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.
Evox Therapeutics announces launch of strategic collaboration with the University of Oxford
General Innovation
18 November 2020
Collaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases
BioEscalator’s resident biotech Base Genomics acquired by Exact Sciences
General Innovation
4 November 2020
Oxford Sciences Innovation (OSI) recently announced the acquisition of its portfolio company, Base Genomics, by US-based early cancer diagnostic leaders, Exact Sciences, for $410m. The partnership will enable Base Genomics to significantly accelerate its clinical and commercial development here in Oxford, potentially unlocking a new era of preventative medicine and improved patient outcomes.
Novel COVID-19 Antibody Therapy Candidates Identified by Leading UK Biotech Consortium
Coronavirus COVID-19 Innovation Research
29 October 2020
Comparison of five tests used to detect COVID-19 antibodies shows Siemens and Oxford assays met regulatory targets
Coronavirus COVID-19 Innovation Research
28 September 2020
New research shows that, in a head-to-head comparison of five tests used to detect COVID-19 antibodies (known as ‘immunoassays’), an assay manufactured by Siemens and one developed by an academic partnership led by the University of Oxford had the most accurate results. The study is published in The Lancet Infectious Diseases.
QUOD enters partnership with Evotec
General Innovation Research
2 September 2020
Evotec SE, a drug discovery and development solutions company, today announced a partnership agreement with the University of Oxford regarding access to biospecimens from the biobank Quality in Organ Donation (QUOD), an initiative of the Nuffield Department of Surgical Sciences (NDS) at the University of Oxford in close collaboration with the National Health Service Blood and Transplant (NHSBT) organisation in the UK.
Professor Fran Platt secures £1M funding over two years for vital Parkinson's Disease research, in collaboration with Pfizer
Awards and Appointments General Innovation Research
4 August 2020
There is an increasing body of genetic and biochemical evidence that points toward lysosomal dysfunction as a risk factor for developing age-related neurodegenerative disorders, including Parkinson’s disease (PD).
Agile start-ups partner with academics to find COVID-19 solutions
Coronavirus COVID-19 General Innovation Research
16 July 2020
Three companies at Oxford’s BioEscalator are developing new detection methods and have discovered potential therapeutics in the fight against COVID-19.
Oxford University to lead a new national programme of AI research to improve lung cancer screening
General Innovation Research
3 July 2020
UK Research and Innovation, Cancer Research UK and industry are investing more than £11 million in an Oxford-led artificial intelligence (AI) research programme to improve the diagnosis of lung cancer and other thoracic diseases.
Ebola vaccine approved for use by the European Commission
General Innovation Research
2 July 2020
The European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford.
Theolytics announced winners of the Santander Pitch Finale
General Innovation
24 June 2020
Following a fantastic event, Theolytics was announced the winner of the BioEscalator’s inaugural Pitch Finale, which was kindly supported by Santander Universities UK.
New partnership aims to significantly reduce the incidence of hip and vertebral fractures
General Innovation Research
16 June 2020
The Capture the Fracture Partnership aims to prevent 250 million fractures by 2025 and combat the global public health burden of osteoporosis.
Imaging platform gets grant to teach frontline staff how to recognise COVID-19
Coronavirus COVID-19 General Innovation
8 June 2020
A team of radiologists and radiographers at Oxford University Hospitals and University of Oxford's Department of Oncology has secured a grant to customise a teaching platform to educate frontline NHS staff to diagnose COVID-19 using chest X-rays and CT scans.
BioEscalator’s inaugural Pitch Battle contest
General Innovation
12 May 2020
The BioEscalator’s inaugural Pitch Battle contest was held digitally at the pizza social on Friday 17 April. Eleven pitches in total were delivered by innovative companies in Oxford's medical research district, covering the broad range of drug discovery, drug development and diagnostics work being undertaken at the BioEscalator.
Landmark partnership announced for development of COVID-19 vaccine
Coronavirus COVID-19 General Innovation
30 April 2020
The University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University.